银屑病调节性T细胞的功能异常及STAT3通路调控机制研究

中华皮肤科杂志 ›› 2016, Vol. 49 ›› Issue (4): 232-237.

银屑病调节性T细胞的功能异常及STAT3通路调控机制研究

杨璐婷¹,李冰¹,张倩¹,党二乐¹,王刚²

1. 第四军医大学西京皮肤医院
2. 第四军医大学西京医院皮肤科

收稿日期:2016-01-26 修回日期:2016-02-17 出版日期:2016-04-15 发布日期:2016-03-28
通讯作者: 王刚 E-mail:xjwgang@fmmu.edu.cn
基金资助:
银屑病发病新机制——角蛋白17介导的免疫紊乱及其靶向治疗;角蛋白17的新功能：调控角质形成细胞的免疫活性

Dysfunction of regulatory T cells in patients with psoriasis and related mechanisms of regulation by the STAT3 signaling pathway

Received:2016-01-26 Revised:2016-02-17 Online:2016-04-15 Published:2016-03-28
Contact: WANG Gang E-mail:xjwgang@fmmu.edu.cn

摘要/Abstract

摘要：

目的研究银屑病患者外周血调节性T细胞（Treg）的功能，探讨与功能异常相关的STAT3信号通路机制。方法寻常性银屑病患者81例，银屑病面积和严重度指数（PASI）评分10 ～ 30，均为慢性斑块状。对照组46例，为健康献血者。采用流式细胞仪检测外周血中Treg细胞的比例，用体外淋巴细胞混合培养方法检测银屑病患者和健康人外周血中Treg细胞的增殖活性及对效应性T细胞（Tresp）的抑制功能，用流式细胞仪及qRT-PCR检测Treg细胞中磷酸化STAT3的比例及分泌促炎因子干扰素γ（IFN-γ）、肿瘤坏死因子α（TNF-α）、白细胞介素17（IL-17）的水平。最后，用STAT3通路抑制剂Stattic V处理银屑病患者Treg细胞，观察其增殖及抑制功能的恢复及分泌促炎因子的变化。结果银屑病患者组外周血Treg细胞数量（6.437% ± 0.186%）与对照组（6.812% ± 0.241%）比较差异无统计学意义（t = 1.224，P ＞ 0.05），但银屑病患者组外周血Treg细胞增殖活性及对Tresp细胞的抑制功能明显降低，磷酸化STAT3表达水平显著升高，分泌促炎因子IFN-γ、TNF-α、IL-17的水平显著升高（均P ＜ 0.05）。经50 μg/L Stattic V作用后，银屑病患者Treg细胞对Tresp抑制率为61.670% ± 4.640%，未处理组为28.820% ± 11.490%，两组差异有统计学意义（P ＜ 0.05）；50 μg/L Stattic V作用后，促炎因子IFN-γ、TNF-α、IL-17 mRNA表达量（2-△△Ct）分别为1.654 ± 0.879、0.850 ± 0.705、0.572 ± 0.135，均显著低于未处理组（分别为23.350 ± 6.721、4.847 ± 1.525、3.095 ± 0.650），差异均有统计学意义（P ＜ 0.05）。结论银屑病患者Treg细胞对Tresp细胞的负向调控功能降低，其机制与STAT3信号通路异常活化有关，抑制STAT3通路的活化有可能一定程度地恢复Treg细胞功能。

Abstract:

Yang Luting, Li Bing, Zhang Qian, Dang Erle, Wang Gang Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi′an 710032, China Corresponding author: Wang Gang, Email: xjwgang@fmmu.edu.cn 【Abstract】 Objective To evaluate the function of regulatory T （Treg） cells in peripheral blood from patients with psoriasis, and to explore the possible role of the STAT3 signaling pathway in Treg cell dysfunction. Methods Totally, 81 patients with psoriasis vulgaris, who all presented with chronic plaques and had a psoriasis area and severity index （PASI） score of 10 - 30, were enrolled into this study. Forty-six healthy blood donors served as the control group. Venous blood samples were collected from these subjects followed by isolation of Treg cells and responder T （Tresp） cells. Flow cytometry was performed to determine the proportion of Treg cells in peripheral blood as well as that of cells secreting phosphorylated-STAT3 （p-STAT3）, interferon γ （IFN-γ）, tumor necrosis factor α （TNF-α） and interleukin 17 （IL-17） in Treg cells, and quantitative real-time PCR （qRT-PCR） to measure the levels of IFN-γ, TNF-α and IL-17 mRNAs in Treg cells. Some Treg cells and Tresp cells were cultured in vitro alone or in combination, and flow cytometry was conducted to estimate cellular proliferative activity on day 7 after stimulation with IL-2. Some patient-derived Treg cells were classified into several groups to be cultured alone or in combination with Tresp cells with or without the presence of the STAT3 pathway inhibitor, Stattic V （10 or 50 μg/L）, for 7 days. Subsequently, flow cytometry was performed to evaluate the proliferative activity of Tresp cells, and qRT-PCR to measure the levels of IFN-γ, TNF-α and IL-17 mRNAs in Treg cells. Results No significant differences were observed in the proportion of Treg cells in peripheral blood between the patient group and control group （6.437% ± 0.186% vs. 6.812% ± 0.241%, t = 1.224, P > 0.05）. Compared with control-derived Treg cells, the patient-derived Treg cells showed significantly decreased proliferative activity and inhibitory effects on Tresp cells, but increased proportion of cells secreting p-STAT3, IFN-γ, TNF-α and IL-17 （all P < 0.05）. After the treatment with 50 μg/L Stattic V, a significant increase was observed in the inhibitory effect of patient-derived Treg cells on Tresp cells （inhibition rate: 61.670% ± 4.640% vs. 28.820% ± 11.490%, P < 0.05）, but a significant decrease in the mRNA s of IFN-γ （2-△△C t : 1.654 ± 0.879 vs. 23.350 ± 6.721, P < 0.05）, TNF-α （0.850 ± 0.705 vs. 4.847 ± 1.525, P < 0.05） and IL-17 （0.572 ± 0.135 vs. 3.095 ± 0.650, all P < 0.05） in patient-derived Treg cells compared with untreated patient-derived Treg cells. Conclusions The negative regulatory effect of Treg cells on Tresp cells is decreased in patients with psoriasis, which may be associated with abnormal activation of the STAT3 signaling pathway, and inhibition of the pathway may restore the function of Treg cells to a certain extent.

杨璐婷李冰张倩党二乐王刚. 银屑病调节性T细胞的功能异常及STAT3通路调控机制研究[J]. 中华皮肤科杂志, 2016, 49(4): 232-237.

参考文献 15

［1］	Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3+CD25+CD4+ natural regulatory T cells in dominant self⁃tolerance and autoimmune disease［J］. Immunol Rev, 2006, 212: 8⁃27. DOI: 10.1111/j.0105⁃2896.2006.00427.x.
［2］	Michalak⁃Stoma A, Pietrzak A, Szepietowski JC, et al. Cytokine network in psoriasis revisited［J］. Eur Cytokine Netw, 2011, 22（4）: 160⁃168. DOI: 10.1684/ecn.2011.0294.
［3］	Reich A, Welz⁃Kubiak K, Rams L. Apprehension of the disease by patients suffering from psoriasis［J］. Postepy Dermatol Alergol, 2014, 31（5）: 289⁃293. DOI: 10.5114/pdia.2014.44010.
［4］	Mesquita D, Cruvinel WM, Araujo JA, et al. Imbalanced of functional surface molecules in regulatory and effector T cells in systemic lupus erythematosus［J］. Braz J Med Biol Res, 2014, 47（8）: 662⁃669. DOI: 10.1590/1414⁃431X20143483.
［5］	Soler DC, Sugiyama H, Young AB, et al. Psoriasis patients exhibit impairment of the high potency CCR5（+） T regulatory cell subset［J］. Clin Immunol, 2013, 149（1）: 111⁃118. DOI: 10.1016/j.clim.2013.06.007.
［6］	Alunno A, Manetti M, Caterbi S, et al. Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications［J］. Mediators Inflamm, 2015, 2015: 751793. DOI: 10.1155/2015/751793.
［7］	Mattozzi C, Salvi M, D′Epiro S, et al. Importance of regulatory T cells in the pathogenesis of psoriasis: review of the literature［J］. Dermatology, 2013, 227（2）: 134⁃145. DOI: 10.1159/000353398.
［8］	Fujimura T, Okuyama R, Ito Y, et al. Profiles of Foxp3+ regulatory T cells in eczematous dermatitis, psoriasis vulgaris and mycosis fungoides［J］. Br J Dermatol, 2008, 158（6）: 1256⁃1263. DOI: 10.1111/j.1365⁃2133.2008.08504.x.
［9］	Yan KX, Fang X, Han L, et al. Foxp3+ regulatory T cells and related cytokines differentially expressed in plaque vs. guttate psoriasis vulgaris［J］. Br J Dermatol, 2010, 163（1）: 48⁃56. DOI: 10.1111/j.1365⁃2133.2010.09742.x.
［10］	Chen L, Shen Z, Wang G, et al. Dynamic frequency of CD4+CD25+Foxp3+ Treg cells in psoriasis vulgaris［J］. J Dermatol Sci, 2008, 51（3）: 200⁃203. DOI: 10.1016/j.jdermsci.2008.04.015.
［11］	Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation［J］. J Immunol, 2005, 174（1）: 164⁃173. DOI:10.4049/jimmunol.174.1.164.
［12］	Sano S, Chan KS, DiGiovanni J. Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases［J］. J Dermatol Sci, 2008, 50（1）: 1⁃14. DOI: 10.1016/j.jdermsci.2007.05.016.
［13］	Sano S, Chan KS, Carbajal S, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model［J］. Nat Med, 2005, 11（1）: 43⁃49. DOI: 10.1038/nm1162.
［14］	Laurence A, Amarnath S, Mariotti J, et al. STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft⁃versus⁃host disease［J］. Immunity, 2012, 37（2）: 209⁃222. DOI: 10.1016/j.immuni.2012.05.027.
［15］	Bovenschen HJ, van de Kerkhof PC, van Erp PE, et al. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL⁃17A⁃producing cells and are found in lesional skin［J］. J Invest Dermatol, 2011, 131（9）: 1853⁃1860. DOI: 10.1038/jid.2011.139.